

Bibliography

Bibliography

- [1] Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. *Nature* 2001;411:342–8. <https://doi.org/10.1038/35077213>.
- [2] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin* 2023;73:17–48. <https://doi.org/10.3322/caac.21763>.
- [3] Lewandowska A, Rudzki M, Rudzki S, Lewandowski T, Laskowska B. Environmental risk factors for cancer – review paper. *Annals of Agricultural and Environmental Medicine* 2019;26:1–7. <https://doi.org/10.26444/aaem/94299>.
- [4] Sapienza C, Issa J-P. Diet, Nutrition, and Cancer Epigenetics. *Annu Rev Nutr* 2016;36:665–81. <https://doi.org/10.1146/annurev-nutr-121415-112634>.
- [5] Caporaso NE, Landi MT. Molecular epidemiology: a new perspective for the study of toxic exposures in man. A consideration of the influence of genetic susceptibility factors on risk in different lung cancer histologies. *Med Lav* 1994;85:68–77.
- [6] Spector LG, Pankratz N, Marcotte EL. Genetic and Nongenetic Risk Factors for Childhood Cancer. *Pediatr Clin North Am* 2015;62:11–25. <https://doi.org/10.1016/j.pcl.2014.09.013>.
- [7] Turati F, Negri E, Vecchia C La. Family history and the risk of cancer: genetic factors influencing multiple cancer sites. *Expert Rev Anticancer Ther* 2014;14:1–4. <https://doi.org/10.1586/14737140.2014.863713>.
- [8] Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell* 2011;144:646–74. <https://doi.org/10.1016/j.cell.2011.02.013>.
- [9] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer Genome Landscapes. *Science* (1979) 2013;339:1546–58. <https://doi.org/10.1126/science.1235122>.
- [10] Loud JT, Murphy J. Cancer Screening and Early Detection in the 21 st Century. *Semin Oncol Nurs* 2017;33:121–8. <https://doi.org/10.1016/j.soncn.2017.02.002>.
- [11] Hanahan D, Weinberg RA. The Hallmarks of Cancer. *Cell* 2000;100:57–70. [https://doi.org/10.1016/S0092-8674\(00\)81683-9](https://doi.org/10.1016/S0092-8674(00)81683-9).
- [12] Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. *Semin Cancer Biol* 2015;35:S25–54. <https://doi.org/10.1016/j.semcancer.2015.02.006>.

- [13] Amin ARM, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, et al. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. *Semin Cancer Biol* 2015;35:S55–77. <https://doi.org/10.1016/j.semcancer.2015.02.005>.
- [14] Fulda S. Tumor resistance to apoptosis. *Int J Cancer* 2009;124:511–5. <https://doi.org/10.1002/ijc.24064>.
- [15] Guterres AN, Villanueva J. Targeting telomerase for cancer therapy. *Oncogene* 2020;39:5811–24. <https://doi.org/10.1038/s41388-020-01405-w>.
- [16] Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors - clinical perspectives. *Cell Oncol (Dordr)* 2021;44:715–37. <https://doi.org/10.1007/s13402-021-00602-3>.
- [17] Saman H, Raza SS, Uddin S, Rasul K. Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. *Cancers (Basel)* 2020;12:1172. <https://doi.org/10.3390/cancers12051172>.
- [18] Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. *Cell Metab* 2016;23:27–47. <https://doi.org/10.1016/J.CMET.2015.12.006>.
- [19] Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. *Nat Rev Cancer* 2021;21:669–80. <https://doi.org/10.1038/S41568-021-00378-6>.
- [20] Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin Cancer Biol* 2015;35 Suppl:S185–98. <https://doi.org/10.1016/J.SEMCANCER.2015.03.004>.
- [21] Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, et al. Inflammation-Induced Tumorigenesis and Metastasis. *Int J Mol Sci* 2021;22:5421. <https://doi.org/10.3390/ijms22115421>.
- [22] Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. *Signal Transduct Target Ther* 2021;6:263. <https://doi.org/10.1038/s41392-021-00658-5>.
- [23] Ho Zhi Guang M, Kavanagh E, Dunne L, Dowling P, Zhang L, Lindsay S, et al. Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. *Cancers (Basel)* 2019;11:66. <https://doi.org/10.3390/cancers11010066>.
- [24] Luo J, Solimini NL, Elledge SJ. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. *Cell* 2009;136:823–37. <https://doi.org/10.1016/j.cell.2009.02.024>.

- [25] Thai AA, Solomon BJ, Sequist L V, Gainor JF, Heist RS. Lung cancer. *The Lancet* 2021;398:535–54. [https://doi.org/https://doi.org/10.1016/S0140-6736\(21\)00312-3](https://doi.org/https://doi.org/10.1016/S0140-6736(21)00312-3).
- [26] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209–49. <https://doi.org/10.3322/caac.21660>.
- [27] Travis WD, Brambilla E, Riely GJ. New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials. *Journal of Clinical Oncology* 2013;31:992–1001. <https://doi.org/10.1200/JCO.2012.46.9270>.
- [28] Lubin JH, Blot WJ. Assessment of Lung Cancer Risk Factors by Histologic Category. *JNCI: Journal of the National Cancer Institute* 1984;73:383–9. <https://doi.org/10.1093/jnci/73.2.383>.
- [29] Hoy H, Lynch T, Beck M. Surgical Treatment of Lung Cancer. *Crit Care Nurs Clin North Am* 2019;31:303–13. <https://doi.org/10.1016/j.cnc.2019.05.002>.
- [30] Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. *Nature* 2018;553:446–54. <https://doi.org/10.1038/nature25183>.
- [31] Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. *Cancer Epidemiology, Biomarkers & Prevention* 2019;28:1563–79. <https://doi.org/10.1158/1055-9965.EPI-19-0221>.
- [32] Mountain CF, Lukeman JM, Hammar SP, Chamberlain DW, Coulson WF, Page DL, et al. Lung cancer classification: The relationship of disease extent and cell type to survival in a clinical trials population. *J Surg Oncol* 1987;35:147–56. <https://doi.org/10.1002/jso.2930350302>.
- [33] Qin J, Lu H. Combined small-cell lung carcinoma. *Onco Targets Ther* 2018;Volume 11:3505–11. <https://doi.org/10.2147/OTT.S159057>.
- [34] Skříčková J, Kadlec B, Venclíček O, Merta Z. Lung cancer. *Cas Lek Cesk* 2018;157:226–36.
- [35] He J, Xu S, Pan H, Li S, He J. Treatments for combined small cell lung cancer patients. *Transl Lung Cancer Res* 2020;9:1785–94. <https://doi.org/10.21037/tlcr-20-437>.
- [36] Schwartz AG, Cote ML. Epidemiology of Lung Cancer. *Adv Exp Med Biol* 2016;893:21–41. https://doi.org/10.1007/978-3-319-24223-1_2.
- [37] Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. *Lung Cancer* 2004;45 Suppl 2. <https://doi.org/10.1016/J.LUNGCAN.2004.07.998>.

- [38] Yang D, Liu Y, Bai C, Wang X, Powell CA. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. *Cancer Lett* 2020;468:82–7. <https://doi.org/10.1016/J.CANLET.2019.10.009>.
- [39] Barnes JL, Zubair M, John K, Poirier MC, Martin FL. Carcinogens and DNA damage. *Biochem Soc Trans* 2018;46:1213–24. <https://doi.org/10.1042/BST20180519>.
- [40] Hecht SS. Tobacco Smoke Carcinogens and Lung Cancer. *JNCI Journal of the National Cancer Institute* 1999;91:1194–210. <https://doi.org/10.1093/jnci/91.14.1194>.
- [41] Darby S, Hill D, Auvinen A, Barros-Dios JM, Baysson H, Bochicchio F, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *BMJ* 2005;330:223. <https://doi.org/10.1136/bmj.38308.477650.63>.
- [42] Riudavets M, Garcia de Herreros M, Besse B, Mezquita L. Radon and Lung Cancer: Current Trends and Future Perspectives. *Cancers (Basel)* 2022;14:3142. <https://doi.org/10.3390/cancers14133142>.
- [43] Spyrtos D, Zarogoulidis P, Porpodis K, Tsakiridis K, Machairiotis N, Katsikogiannis N, et al. Occupational exposure and lung cancer. *J Thorac Dis* 2013;5 Suppl 4:S440-5. <https://doi.org/10.3978/j.issn.2072-1439.2013.07.09>.
- [44] Pohlabeln H, Boffetta P, Ahrens W, Merletti F, Agudo A, Benhamou E, et al. Occupational Risks for Lung Cancer among Nonsmokers. *Epidemiology* 2000;11:532–8. <https://doi.org/10.1097/00001648-200009000-00008>.
- [45] Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. *Nat Genet* 2014;46:736–41. <https://doi.org/10.1038/ng.3002>.
- [46] Cohen AJ, Brauer M, Burnett R, Anderson HR, Frostad J, Estep K, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. *The Lancet* 2017;389:1907–18. [https://doi.org/10.1016/S0140-6736\(17\)30505-6](https://doi.org/10.1016/S0140-6736(17)30505-6).
- [47] Xue Y, Wang L, Zhang Y, Zhao Y, Liu Y. Air pollution: A culprit of lung cancer. *J Hazard Mater* 2022;434:128937. <https://doi.org/10.1016/j.jhazmat.2022.128937>.
- [48] Skoulidis F, Heymach J V. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. *Nat Rev Cancer* 2019;19:495–509. <https://doi.org/10.1038/s41568-019-0179-8>.

- [49] Yue X, Liu J, Feng Z. Tumor suppressor p53 and TRIM family proteins. *Cancer Cell Microenviron* 2015;8–11.
- [50] Watanabe M, Hatakeyama S. JB special review - Recent topics in ubiquitin-proteasome system and autophagy: TRIM proteins and diseases. *J Biochem* 2017;161:135–44. <https://doi.org/10.1093/jb/mvw087>.
- [51] Matassa DS, Agliarulo I, Avolio R, Landriscina M, Esposito F. Trap1 regulation of cancer metabolism: Dual role as oncogene or tumor suppressor. *Genes (Basel)* 2018;9:1–12. <https://doi.org/10.3390/genes9040195>.
- [52] Zhang J guang, Wang J jun, Zhao F, Liu Q, Jiang K, Yang G hai. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). *Clinica Chimica Acta* 2010;411:846–52. <https://doi.org/10.1016/j.cca.2010.02.074>.
- [53] Liu X, Lv X, Yang Q, Jin H, Zhou W, Fan Q. MicroRNA-29a functions as a tumor suppressor and increases cisplatin sensitivity by targeting NRAS in lung cancer. *Technol Cancer Res Treat* 2018;17:1–8. <https://doi.org/10.1177/1533033818758905>.
- [54] Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, et al. A novel epigenetic signature for early diagnosis in lung cancer. *Clinical Cancer Research* 2016;22:3361–71. <https://doi.org/10.1158/1078-0432.CCR-15-2346>.
- [55] Hatakeyama S. TRIM proteins and cancer. *Nat Rev Cancer* 2011;11:792–804. <https://doi.org/10.1038/nrc3139>.
- [56] Greulich H. The genomics of lung adenocarcinoma: Opportunities for targeted therapies. *Genes Cancer* 2010;1. <https://doi.org/10.1177/1947601911407324>.
- [57] Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. *PLoS One* 2009;4. <https://doi.org/10.1371/journal.pone.0004576>.
- [58] Ladanyi M, Pao W. Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond. *Modern Pathology* 2008;21. <https://doi.org/10.1038/modpathol.3801018>.
- [59] Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455. <https://doi.org/10.1038/nature07423>.

- [60] Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. *Lung Cancer* 2013;82. <https://doi.org/10.1016/j.lungcan.2013.07.025>.
- [61] McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet* 2017;49:1126–32. <https://doi.org/10.1038/ng.3892>.
- [62] Hung RJ, Spitz MR, Houlston RS, Schwartz AG, Field JK, Ying J, et al. Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15.33 TERT-CLPTM1L1 Region. *Journal of Thoracic Oncology* 2019;14:1360–9. <https://doi.org/10.1016/j.jtho.2019.04.008>.
- [63] Kiyohara C, Shirakawa T, Hopkin JM. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer. *Environ Health Prev Med* 2002;7:47–59. <https://doi.org/10.1007/BF02897330>.
- [64] Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the Evolution of Non–Small-Cell Lung Cancer. *New England Journal of Medicine* 2017;376:2109–21. <https://doi.org/10.1056/NEJMoa1616288>.
- [65] Shen H, Laird PW. Interplay between the Cancer Genome and Epigenome. *Cell* 2013;153:38–55. <https://doi.org/10.1016/j.cell.2013.03.008>.
- [66] Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. *Front Oncol* 2014;4. <https://doi.org/10.3389/fonc.2014.00204>.
- [67] Hirsch FR, Scagliotti G V, Mulshine JL, Kwon R, Curran WJ, Wu Y-L, et al. Lung cancer: current therapies and new targeted treatments. *The Lancet* 2017;389:299–311. [https://doi.org/10.1016/S0140-6736\(16\)30958-8](https://doi.org/10.1016/S0140-6736(16)30958-8).
- [68] Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012;13:239–46. [https://doi.org/10.1016/S1470-2045\(11\)70393-X](https://doi.org/10.1016/S1470-2045(11)70393-X).

- [69] Cho J, Choi SM, Lee J, Lee C-H, Lee S-M, Kim D-W, et al. Proportion and clinical features of never-smokers with non-small cell lung cancer. *Chin J Cancer* 2017;36:20. <https://doi.org/10.1186/s40880-017-0187-6>.
- [70] Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. *J Thorac Dis* 2010;2:48–51.
- [71] Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:e73. <https://doi.org/10.1371/journal.pmed.0020073>.
- [72] Ricordel C, Friboulet L, Facchinetti F, Soria J-C. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. *Annals of Oncology* 2018;29:i28–37. <https://doi.org/10.1093/annonc/mdx705>.
- [73] Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. *J Thorac Dis* 2011;3:10–8. <https://doi.org/10.3978/j.issn.2072-1439.2010.12.02>.
- [74] Prior IA, Lewis PD, Mattos C. A Comprehensive Survey of Ras Mutations in Cancer. *Cancer Res* 2012;72:2457–67. <https://doi.org/10.1158/0008-5472.CAN-11-2612>.
- [75] Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. *EBioMedicine* 2019;41:711–6. <https://doi.org/10.1016/j.ebiom.2019.02.049>.
- [76] Westcott PMK, To MD. The genetics and biology of KRAS in lung cancer. *Chin J Cancer* 2013;32:63–70. <https://doi.org/10.5732/cjc.012.10098>.
- [77] Drosten M, Barbacid M. Targeting the MAPK Pathway in KRAS-Driven Tumors. *Cancer Cell* 2020;37:543–50. <https://doi.org/10.1016/j.ccell.2020.03.013>.
- [78] Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature* 2019;575:217–23. <https://doi.org/10.1038/s41586-019-1694-1>.
- [79] Nieto P, Ambrogio C, Esteban-Burgos L, Gómez-López G, Blasco MT, Yao Z, et al. A Braf kinase-inactive mutant induces lung adenocarcinoma. *Nature* 2017;548:239–43. <https://doi.org/10.1038/nature23297>.

- [80] Yan N, Guo S, Zhang H, Zhang Z, Shen S, Li X. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. *Front Oncol* 2022;12. <https://doi.org/10.3389/fonc.2022.863043>.
- [81] Guaitoli G, Zullo L, Tiseo M, Dankner M, Rose AA, Facchinetti F. Non-small-cell lung cancer: how to manage BRAF-mutated disease. *Drugs Context* 2023;12:1–19. <https://doi.org/10.7573/dic.2022-11-3>.
- [82] Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol* 2009;27:4247–53. <https://doi.org/10.1200/JCO.2009.22.6993>.
- [83] Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, et al. Crizotinib versus Chemotherapy in Advanced *ALK* -Positive Lung Cancer. *New England Journal of Medicine* 2013;368:2385–94. <https://doi.org/10.1056/NEJMoa1214886>.
- [84] Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res* 2012;18:1472–82. <https://doi.org/10.1158/1078-0432.CCR-11-2906>.
- [85] Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, et al. *MET* Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent *MET* Genomic Amplification and c-Met Overexpression. *Journal of Clinical Oncology* 2016;34:721–30. <https://doi.org/10.1200/JCO.2015.63.4600>.
- [86] Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. *Clin Cancer Res* 2012;18:4910–8. <https://doi.org/10.1158/1078-0432.CCR-12-0912>.
- [87] Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. *Cancer Discov* 2013;3:630–5. <https://doi.org/10.1158/2159-8290.CD-13-0035>.
- [88] Gainor JF, Varghese AM, Ou S-HI, Kabraji S, Awad MM, Katayama R, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. *Clin Cancer Res* 2013;19:4273–81. <https://doi.org/10.1158/1078-0432.CCR-13-0318>.

- [89] Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. *Nat Rev Clin Oncol* 2018;15:151–67. <https://doi.org/10.1038/nrclinonc.2017.175>.
- [90] Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. *Cancer Discov* 2017;7:596–609. <https://doi.org/10.1158/2159-8290.CD-16-1337>.
- [91] Morimoto RI. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. *Genes Dev* 2008;22:1427–38. <https://doi.org/10.1101/gad.1657108>.
- [92] Jayaraj GG, Hipp MS, Hartl FU. Functional Modules of the Proteostasis Network. *Cold Spring Harb Perspect Biol* 2020;12:a033951. <https://doi.org/10.1101/cshperspect.a033951>.
- [93] Höhn A, Tramutola A, Cascella R. Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. *Oxid Med Cell Longev* 2020;2020:1–21. <https://doi.org/10.1155/2020/5497046>.
- [94] McAlary L, Plotkin SS, Cashman NR. Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases. *CNS Drugs* 2019;33:883–904. <https://doi.org/10.1007/s40263-019-00657-9>.
- [95] Sincere NI, Anand K, Ashique S, Yang J, You C. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies. *Molecules* 2023;28:4014. <https://doi.org/10.3390/molecules28104014>.
- [96] Qi S-M, Dong J, Xu Z-Y, Cheng X-D, Zhang W-D, Qin J-J. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy. *Front Pharmacol* 2021;12. <https://doi.org/10.3389/fphar.2021.692574>.
- [97] Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitin-proteasome system. *J Biosci* 2006;31:137–55. <https://doi.org/10.1007/BF02705243>.
- [98] Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. *J Pathol* 2010;221:3–12. <https://doi.org/10.1002/path.2697>.
- [99] Cao W, Li J, Yang K, Cao D. An overview of autophagy: Mechanism, regulation and research progress. *Bull Cancer* 2021;108:304–22. <https://doi.org/10.1016/j.bulcan.2020.11.004>.
- [100] Kroemer G, Mariño G, Levine B. Autophagy and the Integrated Stress Response. *Mol Cell* 2010;40:280–93. <https://doi.org/10.1016/j.molcel.2010.09.023>.

- [101] Marzella L, Ahlberg J, Glaumann H. Autophagy, heterophagy, microautophagy and crinophagy as the means for intracellular degradation. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1981;36:219–34. <https://doi.org/10.1007/BF02912068>.
- [102] Wang L, Klionsky DJ, Shen H-M. The emerging mechanisms and functions of microautophagy. *Nat Rev Mol Cell Biol* 2023;24:186–203. <https://doi.org/10.1038/s41580-022-00529-z>.
- [103] Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. *Cell Res* 2014;24:24–41. <https://doi.org/10.1038/cr.2013.168>.
- [104] Yang Z, Klionsky DJ. An Overview of the Molecular Mechanism of Autophagy, 2009, p. 1–32. https://doi.org/10.1007/978-3-642-00302-8_1.
- [105] Fred Dice J. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. *Trends Biochem Sci* 1990;15:305–9. [https://doi.org/10.1016/0968-0004\(90\)90019-8](https://doi.org/10.1016/0968-0004(90)90019-8).
- [106] Orenstein SJ, Cuervo AM. Chaperone-mediated autophagy: Molecular mechanisms and physiological relevance. *Semin Cell Dev Biol* 2010;21:719–26. <https://doi.org/10.1016/j.semcdb.2010.02.005>.
- [107] Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. *Nat Rev Mol Cell Biol* 2018;19:365–81. <https://doi.org/10.1038/s41580-018-0001-6>.
- [108] Arias E, Cuervo AM. Chaperone-mediated autophagy in protein quality control. *Curr Opin Cell Biol* 2011;23:184–9. <https://doi.org/10.1016/j.ceb.2010.10.009>.
- [109] Yim WW-Y, Mizushima N. Lysosome biology in autophagy. *Cell Discov* 2020;6:6. <https://doi.org/10.1038/s41421-020-0141-7>.
- [110] Clague MJ, Urbé S. Ubiquitin: Same Molecule, Different Degradation Pathways. *Cell* 2010;143:682–5. <https://doi.org/10.1016/j.cell.2010.11.012>.
- [111] Tu Y, Chen C, Pan J, Xu J, Zhou Z-G, Wang C-Y. The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. *Int J Clin Exp Pathol* 2012;5:726–38.
- [112] Kopito RR. Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol* 2000;10:524–30. [https://doi.org/10.1016/S0962-8924\(00\)01852-3](https://doi.org/10.1016/S0962-8924(00)01852-3).
- [113] SCHLESINGER DH, GOLDSTEIN G. Molecular conservation of 74 amino acid sequence of ubiquitin between cattle and man. *Nature* 1975;255:423–4. <https://doi.org/10.1038/255423a0>.

- [114] Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. *Proceedings of the National Academy of Sciences* 1975;72:11–5. <https://doi.org/10.1073/pnas.72.1.11>.
- [115] Hershko A, Ciechanover A, Rose IA. Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. *Proceedings of the National Academy of Sciences* 1979;76:3107–10. <https://doi.org/10.1073/pnas.76.7.3107>.
- [116] Hershko A, Heller H, Elias S, Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. *J Biol Chem* 1983;258:8206–14.
- [117] Livneh I, Cohen-Kaplan V, Cohen-Rosenzweig C, Avni N, Ciechanover A. The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. *Cell Res* 2016;26:869–85. <https://doi.org/10.1038/cr.2016.86>.
- [118] Chowdhury M, Enenkel C. Intracellular Dynamics of the Ubiquitin-Proteasome-System. *F1000Res* 2015;4:367. <https://doi.org/10.12688/F1000RESEARCH.6835.2>.
- [119] Rape M. Ubiquitylation at the crossroads of development and disease. *Nat Rev Mol Cell Biol* 2018;19:59–70. <https://doi.org/10.1038/NRM.2017.83>.
- [120] Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy. *Oncologist* 2003;8:508–13. <https://doi.org/10.1634/theoncologist.8-6-508>.
- [121] Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. *Proceedings of the National Academy of Sciences* 2001;98:8554–9. <https://doi.org/10.1073/pnas.141230798>.
- [122] Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future. *Drug Discov Today Technol* 2019;31:15–27. <https://doi.org/10.1016/j.ddtec.2019.01.002>.
- [123] Sampson C, Wang Q, Otkur W, Zhao H, Lu Y, Liu X, et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. *Clin Transl Med* 2023;13. <https://doi.org/10.1002/ctm2.1204>.

- [124] Goyani S, Roy M, Singh R. TRIM-NHL as RNA Binding Ubiquitin E3 Ligase (RBUL): Implication in development and disease pathogenesis. *Biochim Biophys Acta Mol Basis Dis* 2021;1867:166066. <https://doi.org/10.1016/j.bbadis.2020.166066>.
- [125] Zang S. TRIM32 overexpression improves chemoresistance through regulation of mitochondrial function in non-small-cell lung cancers 2018:7841–52.
- [126] Czerwińska P, Mazurek S, Wiznerowicz M. The complexity of TRIM28 contribution to cancer. *J Biomed Sci* 2017;24:1–14. <https://doi.org/10.1186/s12929-017-0374-4>.
- [127] Yi J, Huang D, Li X, Jiang G, Dong J, Liu Y. TRIM26 acts as a tumor suppressor in non-small-cell lung cancer. *Int J Clin Exp Pathol* 2016;9:6385–90.
- [128] Zhan W, Zhang S. TRIM proteins in lung cancer: Mechanisms, biomarkers and therapeutic targets. *Life Sci* 2021;268:118985. <https://doi.org/10.1016/j.lfs.2020.118985>.
- [129] Huang N, Sun X, Li P, liu X, Zhang X, Chen Q, et al. TRIM family contribute to tumorigenesis, cancer development, and drug resistance. *Exp Hematol Oncol* 2022;11:75. <https://doi.org/10.1186/s40164-022-00322-w>.
- [130] Bhaduri U, Merla G. Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity. *Cells* 2021;10:1015. <https://doi.org/10.3390/cells10051015>.
- [131] Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. *Cell Res* 2016;26:484–98. <https://doi.org/10.1038/cr.2016.31>.
- [132] George AJ, Hoffiz YC, Charles AJ, Zhu Y, Mabb AM. A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders. *Front Genet* 2018;9. <https://doi.org/10.3389/fgene.2018.00029>.
- [133] Bi PML, Rlfcrkdmvievclersqe AEKL, Hlfcekdgkalcwvcaqrk AERL, Klyceedqmpicvvcdsrre EEPL, Klyckddgtlscvicrdsrk SERL. PROTEIN SEQUENCE MOTIFS 1992:344–5.
- [134] Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. *Cde221* 2001;20.
- [135] Borden KLB, Freemont PS. The RING finger domain: A recent example of a sequence-structure family. *Curr Opin Struct Biol* 1996;6:395–401. [https://doi.org/10.1016/S0959-440X\(96\)80060-1](https://doi.org/10.1016/S0959-440X(96)80060-1).
- [136] Borden KLB. RING fingers and B-boxes: zinc-binding protein-protein interaction domains. *Biochemistry and Cell Biology* 1998;76:351–8. <https://doi.org/10.1139/bcb-76-2-3-351>.

- [137] Lovering R, Hanson IM, Borden KLB, Martin S, O'Reilly NJ, Evan GI, et al. Identification and preliminary characterization of a protein motif related to the zinc finger. *Proc Natl Acad Sci U S A* 1993;90:2112–6. <https://doi.org/10.1073/pnas.90.6.2112>.
- [138] Joazeiro CAP, Weissman AM. RING finger proteins: Mediators of ubiquitin ligase activity. *Cell* 2000;102:549–52. [https://doi.org/10.1016/S0092-8674\(00\)00077-5](https://doi.org/10.1016/S0092-8674(00)00077-5).
- [139] Massiah MA, Matts JAB, Short KM, Simmons BN, Singireddy S, Yi Z, et al. Solution Structure of the MID1 B-box2 CHC(D/C)C2H2 Zinc-binding Domain: Insights into an Evolutionarily Conserved RING Fold. *J Mol Biol* 2007;369:1–10. <https://doi.org/10.1016/j.jmb.2007.03.017>.
- [140] Short KM, Cox TC. Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. *Journal of Biological Chemistry* 2006;281:8970–80. <https://doi.org/10.1074/jbc.M512755200>.
- [141] Torok M, Etkin LD. Two B or not two B? Overview of the rapidly expanding B-box family of proteins. *Differentiation* 2001;67:63–71. <https://doi.org/10.1046/j.1432-0436.2001.067003063.x>.
- [142] Massiah MA, Simmons BN, Short KM, Cox TC. Solution Structure of the RBCC/TRIM B-box1 Domain of Human MID1: B-box with a RING. *J Mol Biol* 2006;358:532–45. <https://doi.org/10.1016/j.jmb.2006.02.009>.
- [143] Goldstone DC, Walker PA, Calder LJ, Coombs PJ, Kirkpatrick J, Ball NJ, et al. Structural studies of postentry restriction factors reveal antiparallel dimers that enable avid binding to the HIV-1 capsid lattice. *Proc Natl Acad Sci U S A* 2014;111:9609–14. <https://doi.org/10.1073/pnas.1402448111>.
- [144] Diaz-Griffero F, Qin X -r., Hayashi F, Kigawa T, Finzi A, Sarnak Z, et al. A B-Box 2 Surface Patch Important for TRIM5 Self-Association, Capsid Binding Avidity, and Retrovirus Restriction. *J Virol* 2009;83:10737–51. <https://doi.org/10.1128/jvi.01307-09>.
- [145] Li X, Yeung DF, Fiegen AM, Sodroski J. Determinants of the higher order association of the restriction factor TRIM5 α and other tripartite motif (TRIM) proteins. *Journal of Biological Chemistry* 2011;286:27959–70. <https://doi.org/10.1074/jbc.M111.260406>.
- [146] Tao H, Simmons BN, Singireddy S, Jakkidi M, Short KM, Cox TC, et al. Structure of the MID1 Tandem B-Boxes Reveals an Interaction Reminiscent of. *Biochemistry* 2008;47:2450–7.
- [147] Streich FC, Ronchi VP, Connick JP, Haas AL. Tripartite motif ligases catalyze polyubiquitin chain formation through a cooperative allosteric mechanism. *Journal of Biological Chemistry* 2013;288:8209–21. <https://doi.org/10.1074/jbc.M113.451567>.

- [148] Sanchez JG, Okreglicka K, Chandrasekaran V, Welker JM, Sundquist WI, Pornillos O. The tripartite motif coiled-coil is an elongated antiparallel hairpin dimer. *Proc Natl Acad Sci U S A* 2014;111:2494–9. <https://doi.org/10.1073/pnas.1318962111>.
- [149] Napolitano LM, Meroni G. TRIM family: Pleiotropy and diversification through homomultimer and heteromultimer formation. *IUBMB Life* 2012;64:64–71. <https://doi.org/10.1002/iub.580>.
- [150] Koliopoulos MG, Esposito D, Christodoulou E, Taylor IA, Rittinger K. Functional role of TRIM E3 ligase oligomerization and regulation of catalytic activity . *EMBO J* 2016;35:1204–18. <https://doi.org/10.15252/embj.201593741>.
- [151] Nisole S, Stoye JP, Saïb A. TRIM family proteins: Retroviral restriction and antiviral defence. *Nat Rev Microbiol* 2005;3:799–808. <https://doi.org/10.1038/nrmicro1248>.
- [152] Esposito D, Koliopoulos MG, Rittinger K. Structural determinants of TRIM protein function. *Biochem Soc Trans* 2017;45:183–91. <https://doi.org/10.1042/BST20160325>.
- [153] Sardiello M, Cairo S, Fontanella B, Ballabio A, Meroni G. Genomic analysis of the TRIM family reveals two groups of genes with distinct evolutionary properties. *BMC Evol Biol* 2008;8. <https://doi.org/10.1186/1471-2148-8-225>.
- [154] Hatakeyama S. TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis. *Trends Biochem Sci* 2017;42:297–311. <https://doi.org/10.1016/j.tibs.2017.01.002>.
- [155] Kikuchi M, Okumura F, Tsukiyama T, Watanabe M, Miyajima N, Tanaka J, et al. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* 2009;1793:1828–36. <https://doi.org/10.1016/j.bbamcr.2009.11.001>.
- [156] Okumura F, Matsunaga Y, Katayama Y, Nakayama KI, Hatakeyama S. TRIM8 modulates STAT3 activity through negative regulation of PIAS3. *J Cell Sci* 2010;123:2238–45. <https://doi.org/10.1242/jcs.068981>.
- [157] Masuda Y, Takahashi H, Sato S, Tomomori-Sato C, Saraf A, Washburn MP, et al. TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. *Nat Commun* 2015;6:7299. <https://doi.org/10.1038/ncomms8299>.
- [158] Watanabe M, Tsukiyama T, Hatakeyama S. TRIM31 interacts with p52Shc and inhibits Src-induced anchorage-independent growth. *Biochem Biophys Res Commun* 2009;388:422–7. <https://doi.org/10.1016/j.bbrc.2009.08.028>.

- [159] Kano S, Miyajima N, Fukuda S, Hatakeyama S. Tripartite Motif Protein 32 Facilitates Cell Growth and Migration via Degradation of Abl-Interactor 2. *Cancer Res* 2008;68:5572–80. <https://doi.org/10.1158/0008-5472.CAN-07-6231>.
- [160] Wang Y, Yan S, Yang B, Wang Y, Zhou H, Lian Q, et al. TRIM35 negatively regulates TLR7- and TLR9-mediated type I interferon production by targeting IRF7. *FEBS Lett* 2015;589:1322–30. <https://doi.org/10.1016/J.FEBSLET.2015.04.019>.
- [161] Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F, Pelicci PG. TRIM proteins in cancer. *Adv Exp Med Biol* 2012;770:77–91. https://doi.org/10.1007/978-1-4614-5398-7_6.
- [162] Cammas F, Mark M, Dollé P, Dierich A, Chambon P, Losson R. Mice lacking the transcriptional corepressor TIF1 β are defective in early postimplantation development. *Development* 2000;127:2955–63.
- [163] Jaworska AM, Wlodarczyk NA, Mackiewicz A, Czerwinska P. The role of TRIM family proteins in the regulation of cancer stem cell self-renewal. *Stem Cells* 2020;38:165–73. <https://doi.org/10.1002/stem.3109>.
- [164] Mandell MA, Jain A, Arko-mensah J, Chauhan S, Dinkins C, Silvestri G, et al. NIH Public Access 2015;30:394–409. <https://doi.org/10.1016/j.devcel.2014.06.013>.TRIM.
- [165] Baranzini S, Wang J, ... RG-H molecular, 2009 undefined. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. AcademicOupCom n.d.
- [166] Martins-De-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2009;259:151–63. <https://doi.org/10.1007/S00406-008-0847-2>.
- [167] Arra M, Emanuele E, Martinelli V, Minoretti P, Bertona M, Geroldi D. The M694V Variant of the Familial Mediterranean Fever Gene Is Associated with Sporadic Early-Onset Alzheimer's Disease in an Italian Population Sample. *Dement Geriatr Cogn Disord* 2007;23:55–9. <https://doi.org/10.1159/000096743>.
- [168] Quaderi N, Schweiger S, Gaudenz K, ... BF-N, 1997 undefined. Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22. NatureCom n.d.
- [169] Micale L, Fusco C, Augello B, ... LN-E journal of, 2008 undefined. Williams–Beuren syndrome TRIM50 encodes an E3 ubiquitin ligase. NatureCom n.d.

- [170] Wang X, Zhu H, Snieder H, Su S, Munn D, Harshfield G, et al. Obesity related methylation changes in DNA of peripheral blood leukocytes. *BMC Med* 2010;8. <https://doi.org/10.1186/1741-7015-8-87>.
- [171] Grimaldi MP, Candore G, Vasto S, Caruso M, Caimi G, Hoffmann E, et al. Role of the pyrin M694V (A2080G) allele in acute myocardial infarction and longevity: a study in the Sicilian population. *Wiley Online Library* 2006;79:611–5. <https://doi.org/10.1189/jlb.0705416>.
- [172] Chen SN, Czernuszewicz G, Tan Y, Lombardi R, Jin J, Willerson JT, et al. Human molecular genetic and functional studies identify TRIM63, encoding muscle RING finger protein 1, as a novel gene for human hypertrophic cardiomyopathy. *Circ Res* 2012;111:907–19. <https://doi.org/10.1161/CIRCRESAHA.112.270207>.
- [173] Stremlau M, Owens C, Perron M, Nature MK-, 2004 undefined. The cytoplasmic body component TRIM5 α restricts HIV-1 infection in Old World monkeys. *NatureCom* n.d.
- [174] Tissot C, Chemistry NM-J of B, 1995 undefined. Molecular Cloning of a New Interferon-induced Factor That Represses Human Immunodeficiency Virus Type 1 Long Terminal Repeat Expression (*). *ASBMB* n.d.
- [175] Tang Z-P, Dong Q-Z, Cui Q-Z, Papavassiliou P, Wang E-D, Wang E-H. Ataxia-Telangiectasia Group D Complementing Gene (ATDC) Promotes Lung Cancer Cell Proliferation by Activating NF- κ B Pathway. *PLoS One* 2013;8:e63676. <https://doi.org/10.1371/journal.pone.0063676>.
- [176] Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a Zinc Finger Gene Disrupted by the t(15;17) in Acute Promyelocytic Leukemia. *Science* (1979) 1991;254:1371–4. <https://doi.org/10.1126/science.1720570>.
- [177] Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty VVVS, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR α with a novel putative transcription factor, PML. *Cell* 1991;66:663–74. [https://doi.org/10.1016/0092-8674\(91\)90112-C](https://doi.org/10.1016/0092-8674(91)90112-C).
- [178] de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR α fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. *Cell* 1991;66:675–84. [https://doi.org/10.1016/0092-8674\(91\)90113-D](https://doi.org/10.1016/0092-8674(91)90113-D).
- [179] Khetchoumian K, Teletin M, Tisserand J, ... MM-N, 2007 undefined. Loss of Trim24 (Tif1 α) gene function confers oncogenic activity to retinoic acid receptor alpha. *NatureCom* n.d.

- [180] Cao T, Mark I, Mary S?, Handel A, And ?, Etkin1 LD. Mouse ret finger protein (rfp) proto-oncogene is expressed at specific stages of mouse spermatogenesis. Wiley Online Library 1996;19:309–20. [https://doi.org/10.1002/\(SICI\)1520-6408\(1996\)19:4<309::AID-DVG4>3.0.CO;2-D](https://doi.org/10.1002/(SICI)1520-6408(1996)19:4<309::AID-DVG4>3.0.CO;2-D).
- [181] Dho S, Chemistry KK-J of B, 2003 undefined. The Ret finger protein induces apoptosis via its RING finger-B box-coiled-coil motif. ASBMB n.d.
- [182] Ma X, Ma X, Qiu Y, Zhu L, Lin Y, You Y, et al. TRIM50 suppressed hepatocarcinoma progression through directly targeting SNAIL for ubiquitous degradation. Cell Death Dis 2018;9:608. <https://doi.org/10.1038/s41419-018-0644-4>.
- [183] Li R, Zhu L, Peng Y, Zhang X, Dai C, Liu D. TRIM50 Suppresses Pancreatic Cancer Progression and Reverses the Epithelial-Mesenchymal Transition via Facilitating the Ubiquitous Degradation of Snail1. Front Oncol 2021;11. <https://doi.org/10.3389/fonc.2021.695740>.
- [184] Liu M, Zhang X, Cai J, Li Y, Luo Q, Wu H, et al. Downregulation of TRIM58 expression is associated with a poor patient outcome and enhances colorectal cancer cell invasion. Oncol Rep 2018. <https://doi.org/10.3892/or.2018.6525>.
- [185] McAvera RM, Crawford LJ. TIF1 Proteins in Genome Stability and Cancer. Cancers (Basel) 2020;12:2094. <https://doi.org/10.3390/cancers12082094>.
- [186] Xu M, Hu J, Zhou B, Zhong Y, Lin N, Xu R. TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/β-catenin signaling pathway. Acta Biochim Biophys Sin (Shanghai) 2018;51:68–77. <https://doi.org/10.1093/abbs/gmy151>.
- [187] Zhou Z-Y, Yang G-Y, Zhou J, Yu M-H. Significance of TRIM29 and β-catenin expression in non-small-cell lung cancer. Journal of the Chinese Medical Association 2012;75:269–74. <https://doi.org/10.1016/j.jcma.2012.04.015>.
- [188] SONG X, FU C, YANG X, SUN D, ZHANG X, ZHANG J. Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer. Oncol Lett 2015;10:2283–8. <https://doi.org/10.3892/ol.2015.3623>.
- [189] Li H, Sun L, Tang Z, Fu L, Xu Y, Li Z, et al. Overexpression of TRIM24 Correlates with Tumor Progression in Non-Small Cell Lung Cancer. PLoS One 2012;7:e37657. <https://doi.org/10.1371/journal.pone.0037657>.
- [190] PDQ Adult Treatment Editorial Board. Non-Small Cell Lung Cancer Treatment (PDQ®): Patient Version. 2002.

- [191] Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network* 2022;20:497–530. <https://doi.org/10.6004/jnccn.2022.0025>.
- [192] Whitson BA, Andrade RS, Boettcher A, Bardales R, Kratzke RA, Dahlberg PS, et al. Video-Assisted Thoracoscopic Surgery is More Favorable Than Thoracotomy for Resection of Clinical Stage I Non-Small Cell Lung Cancer. *Ann Thorac Surg* 2007;83:1965–70. <https://doi.org/10.1016/j.athoracsur.2007.01.049>.
- [193] Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic Body Radiation Therapy in Multiple Organ Sites. *Journal of Clinical Oncology* 2007;25:947–52. <https://doi.org/10.1200/JCO.2006.09.7469>.
- [194] Rodrigues G, Videtic GMM, Sur R, Bezjak A, Bradley J, Hahn CA, et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. *Pract Radiat Oncol* 2011;1:60–71. <https://doi.org/10.1016/j.prro.2011.01.005>.
- [195] Pignon J-P, Tribodet H, Scagliotti G V., Douillard J-Y, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. *Journal of Clinical Oncology* 2008;26:3552–9. <https://doi.org/10.1200/JCO.2007.13.9030>.
- [196] Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. *New England Journal of Medicine* 2018;379:2040–51. <https://doi.org/10.1056/NEJMoa1810865>.
- [197] Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *The Lancet* 2016;387:1540–50. [https://doi.org/10.1016/S0140-6736\(15\)01281-7](https://doi.org/10.1016/S0140-6736(15)01281-7).
- [198] Chen L, Chen F, Li J, Pu Y, Yang C, Wang Y, et al. <scp>CAR-T</scp> cell therapy for lung cancer: Potential and perspective. *Thorac Cancer* 2022;13:889–99. <https://doi.org/10.1111/1759-7714.14375>.
- [199] Zulfiqar B, Farooq A, Kanwal S, Asghar K. Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives. *Front Pharmacol* 2022;13. <https://doi.org/10.3389/fphar.2022.1035171>.

- [200] Wu J, Lin Z. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. *Int J Mol Sci* 2022;23:15056. <https://doi.org/10.3390/ijms232315056>.
- [201] Ikeda H, Old LJ, Schreiber RD. The roles of IFN γ in protection against tumor development and cancer immunoediting. *Cytokine Growth Factor Rev* 2002;13:95–109. [https://doi.org/10.1016/S1359-6101\(01\)00038-7](https://doi.org/10.1016/S1359-6101(01)00038-7).
- [202] Fenton SE, Saleiro D, Plataniias LC. Type I and II Interferons in the Anti-Tumor Immune Response. *Cancers (Basel)* 2021;13:1037. <https://doi.org/10.3390/cancers13051037>.
- [203] Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. *Nat Rev Immunol* 2015;15:405–14. <https://doi.org/10.1038/nri3845>.
- [204] Zhang X, Wang S, Zhu Y, Zhang M, Zhao Y, Yan Z, et al. Double-edged effects of interferons on the regulation of cancer-immunity cycle. *Oncoimmunology* 2021;10. <https://doi.org/10.1080/2162402X.2021.1929005>.
- [205] Ruiz-Cordero R, Devine WP. Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer. *Surg Pathol Clin* 2020;13:17–33. <https://doi.org/10.1016/j.path.2019.11.002>.
- [206] Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. *Cellular and Molecular Life Sciences* 2022;79:191. <https://doi.org/10.1007/s00018-022-04219-z>.
- [207] Kirkwood J. Cancer immunotherapy: The interferon- α experience. *Semin Oncol* 2002;29:18–26. <https://doi.org/10.1053/sonc.2002.33078>.
- [208] Park Y, Han SJ. Interferon Signaling in the Endometrium and in Endometriosis. *Biomolecules* 2022;12:1554. <https://doi.org/10.3390/biom12111554>.
- [209] Carthagen L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, et al. Human TRIM Gene Expression in Response to Interferons. *PLoS One* 2009;4:e4894. <https://doi.org/10.1371/journal.pone.0004894>.
- [210] Gao B, Duan Z, Xu W, Xiong S. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. *Hepatology* 2009;50:424–33. <https://doi.org/10.1002/hep.23011>.
- [211] Wang J, Liu B, Wang N, Lee Y-M, Liu C, Li K. TRIM56 Is a Virus- and Interferon-Inducible E3 Ubiquitin Ligase That Restricts Pestivirus Infection. *J Virol* 2011;85:3733–45. <https://doi.org/10.1128/JVI.02546-10>.

- [212] Zhu Q, Yu T, Gan S, Wang Y, Pei Y, Zhao Q, et al. TRIM24 facilitates antiviral immunity through mediating K63-linked TRAF3 ubiquitination. *Journal of Experimental Medicine* 2020;217. <https://doi.org/10.1084/jem.20192083>.
- [213] Maarifi G, Smith N, Maillet S, Moncorgé O, Chamontin C, Edouard J, et al. TRIM8 is required for virus-induced IFN response in human plasmacytoid dendritic cells. *Sci Adv* 2019;5. <https://doi.org/10.1126/sciadv.aax3511>.
- [214] Orimo A, Tominaga N, Yoshimura K, Yamauchi Y, Nomura M, Sato M, et al. Molecular Cloning of Ring Finger Protein 21 (RNF21)/Interferon-Responsive Finger Protein (ifp1), Which Possesses Two RING–B Box–Coiled Coil Domains in Tandem. *Genomics* 2000;69:143–9. <https://doi.org/10.1006/geno.2000.6318>.
- [215] Li X, Gold B, O’huigin C, Diaz-Griffero F, Song B, Virology ZS-, et al. Unique features of TRIM5 α among closely related human TRIM family members. Elsevier n.d.
- [216] Orozco L, Cokus S, ... AG-H molecular, 2009 undefined. Copy number variation influences gene expression and metabolic traits in mice. AcademicOupCom n.d.
- [217] Kaut O, Schmitt I, Tost J, Busato F, Liu Y, Hofmann P, et al. Epigenome-wide DNA methylation analysis in siblings and monozygotic twins discordant for sporadic Parkinson’s disease revealed different epigenetic patterns in peripheral blood mononuclear cells. *Neurogenetics* 2017;18:7–22. <https://doi.org/10.1007/S10048-016-0497-X>.
- [218] Lian Q, Yan S, Yin Q, Yan C, Zheng W, Gu W, et al. TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity. *Cell Mol Immunol* 2021;18:350–62. <https://doi.org/10.1038/s41423-020-0366-2>.
- [219] Campling B, Pym J, Baker H, Cole S, Lam Y-M. Chemosensitivity testing of small cell lung cancer using the MTT assay. *Br J Cancer* 1991;63:75–83. <https://doi.org/10.1038/bjc.1991.16>.
- [220] Arenas AM, Ruiz-Jiménez JM, López-Hidalgo JL, Sanjuán-Hidalgo J, Medina PP. Defining the first *bona fide* cell model for <sc>SMARCA4</sc> -deficient, undifferentiated tumor. *J Pathol* 2023;261:5–10. <https://doi.org/10.1002/path.6141>.
- [221] Yuan B-Z, Jefferson AM, Popescu NC, Reynolds SH. Aberrant Gene Expression in Human Non Small Cell Lung Carcinoma Cells Exposed to Demethylating Agent 5-Aza-2’-Deoxycytidine. *Neoplasia* 2004;6:412–9. <https://doi.org/10.1593/neo.03490>.
- [222] Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2– $\Delta\Delta$ CT Method. *Methods* 2001;25:402–8. <https://doi.org/10.1006/meth.2001.1262>.

- [223] Vicidomini G. Current Challenges and Future Advances in Lung Cancer: Genetics, Instrumental Diagnosis and Treatment. *Cancers (Basel)* 2023;15:3710. <https://doi.org/10.3390/cancers15143710>.
- [224] Dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and Prevention. *Clin Chest Med* 2011;32:605–44. <https://doi.org/10.1016/j.ccm.2011.09.001>.
- [225] Miller JFAP, Sadelain M. The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy. *Cancer Cell* 2015;27:439–49. <https://doi.org/10.1016/j.ccell.2015.03.007>.
- [226] Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. *Nat Rev Immunol* 2006;6:836–48. <https://doi.org/10.1038/nri1961>.
- [227] Kotredes KP, Gamero AM. Interferons as Inducers of Apoptosis in Malignant Cells. *Journal of Interferon & Cytokine Research* 2013;33:162–70. <https://doi.org/10.1089/jir.2012.0110>.
- [228] Mohammadi A, Pour Abbasi MS, Khorrami S, Khodamoradi S, Mohammadi Goldar Z, Ebrahimzadeh F. The TRIM proteins in cancer: from expression to emerging regulatory mechanisms. *Clinical and Translational Oncology* 2022;24:460–70. <https://doi.org/10.1007/s12094-021-02715-5>.
- [229] Meroni G, Desagher S. Cellular Function of TRIM E3 Ubiquitin Ligases in Health and Disease. *Cells* 2022;11:250. <https://doi.org/10.3390/cells11020250>.
- [230] Haglund K, Dikic I. Ubiquitylation and cell signaling. *EMBO J* 2005;24:3353–9. <https://doi.org/10.1038/sj.emboj.7600808>.
- [231] Li Y, Ma C, Zhou T, Liu Y, Sun L, Yu Z. TRIM65 negatively regulates p53 through ubiquitination. *Biochem Biophys Res Commun* 2016;473:278–82. <https://doi.org/10.1016/j.bbrc.2016.03.093>.
- [232] Li S, Wang L, Fu B, Berman MA, Diallo A, Dorf ME. TRIM65 regulates microRNA activity by ubiquitination of TNRC6. *Proc Natl Acad Sci U S A* 2014;111:6970–5. <https://doi.org/10.1073/pnas.1322545111>.
- [233] Peng X, Wen Y, Zha L, Zhuang J, Lin L, Li X, et al. TRIM45 Suppresses the Development of Non-small Cell Lung Cancer. *Curr Mol Med* 2019;20:299–306. <https://doi.org/10.2174/1566524019666191017143833>.

- [234] Zhang Y, Du H, Li Y, Yuan Y, Chen B, Sun S. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma. *Cancer Sci* 2020;111:637–46. <https://doi.org/10.1111/cas.14226>.
- [235] Wang X, Shi W, Shi H, Lu S, Wang K, Sun C, et al. TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells. *Journal of Experimental and Clinical Cancer Research* 2016;35:1–9. <https://doi.org/10.1186/s13046-016-0379-y>.
- [236] Yin H, Chen J. Expression and the potential functions of TRIM32 in lung cancer tumorigenesis 2018:1–12. <https://doi.org/10.1002/jcb.27798>.
- [237] Qin Y, Cui H, Zhang H. Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression. *Technol Cancer Res Treat* 2016;15:707–15. <https://doi.org/10.1177/1533034615595903>.
- [238] Mu X, Li H, Zhou L, Xu W. TRIM52 regulates the proliferation and invasiveness of lung cancer cells via the Wnt/ β -catenin pathway. *Oncol Rep* 2019;41:3325–34. <https://doi.org/10.3892/or.2019.7110>.
- [239] Liu J, Wu W, Xie Y, Lv X, Ling D, Yang Z. Overexpression of TRIM66 functions as an oncogene in lung cancer progression. *Int J Clin Exp Pathol* 2016;9:4966–77.
- [240] Ding Y, Lu Y, Xie X, Sheng B, Wang Z. Silencing TRIM37 inhibits the proliferation and migration of non-small cell lung cancer cells 2018:36852–7. <https://doi.org/10.1039/C8RA06391E>.
- [241] Wang X, Shu Y, Shi H, Lu S, Wang K, Sun C, et al. TRIM9 is up-regulated in human lung cancer and involved in cell proliferation and apoptosis. *Int J Clin Exp Med* 2016;9:10461–9.
- [242] Lin Z, Lin X, Zhu L, Huang J, Huang Y. TRIM2 directly deubiquitinates and stabilizes Snail1 protein, mediating proliferation and metastasis of lung adenocarcinoma. *Cancer Cell Int* 2020;20:1–14. <https://doi.org/10.1186/s12935-020-01316-6>.
- [243] Li H, Zhang Y, Zhang Y, Bai X, Peng Y, He P. TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor. *Tumor Biology* 2014;35:5747–52. <https://doi.org/10.1007/s13277-014-1763-x>.
- [244] Lv XD, Xie YH, Wu WX, Liu JL, Ling DY, Yang ZP. Inhibition of tumor cell adhesion, invasion and migration in human lung cancer cells by silencing of TRIM27. *Int J Clin Exp Pathol* 2016;9:10179–87.

- [245] Liu L, Zhao E, Li C, Huang L, Xiao L, Cheng L, et al. TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer. *Cancer Epidemiol* 2013;37:71–8. <https://doi.org/10.1016/j.canep.2012.08.005>.
- [246] Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, et al. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. *Journal of Pathology* 2014;234:108–19. <https://doi.org/10.1002/path.4385>.
- [247] Hai J, Zhu C, Wang T, Organ SL, Shepherd FA. TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer 2017;1–13. <https://doi.org/10.1038/srep39692>.
- [248] Ma Y, Dai H, Zhang F, Zhao D. TRIM66 expression in non-small cell lung cancer : A new predictor of prognosis 2017;20:309–15. <https://doi.org/10.3233/CBM-170207>.
- [249] Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, et al. Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy. *Mol Cancer Ther* 2011;10:336–46. <https://doi.org/10.1158/1535-7163.MCT-10-0750>.
- [250] Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF, Soussi T. Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment. *Hum Mutat* 2014;35:756–65. <https://doi.org/10.1002/humu.22556>.
- [251] Korrodi-Gregório L, Soto-Cerrato V, Vitorino R, Fardilha M, Pérez-Tomás R. From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research. *PLoS One* 2016;11:e0165973. <https://doi.org/10.1371/journal.pone.0165973>.
- [252] Wroblewski JM, Bixby DL, Borowski C, Yannelli JR. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. *Lung Cancer* 2001;33:181–94. [https://doi.org/10.1016/S0169-5002\(01\)00210-0](https://doi.org/10.1016/S0169-5002(01)00210-0).
- [253] Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress. *American Society of Clinical Oncology Educational Book* 2021:e105–27. https://doi.org/10.1200/EDBK_321483.
- [254] Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. *Molecular Cancer* 2023 22:1 2023;22:1–37. <https://doi.org/10.1186/S12943-023-01740-Y>.

- [255] Bekisz J, Sato Y, Johnson C, Husain SR, Puri RK, Zoon KC. Immunomodulatory Effects of Interferons in Malignancies. *Journal of Interferon & Cytokine Research* 2013;33:154. <https://doi.org/10.1089/JIR.2012.0167>.
- [256] Wang L, Ning S. TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense. *Viruses* 2021;13:279. <https://doi.org/10.3390/v13020279>.
- [257] McNab FW, Rajsbaum R, Stoye JP, O'Garra A. Tripartite-motif proteins and innate immune regulation. *Curr Opin Immunol* 2011;23:46–56. <https://doi.org/10.1016/j.coi.2010.10.021>.
- [258] Carthagen L, Parise MC, Ringeard M, Chelbi-Alix MK, Hazan U, Nisole S. Implication of TRIMalpha and TRIMCyp in interferon-induced anti-retroviral restriction activities. *Retrovirology* 2008;5:59. <https://doi.org/10.1186/1742-4690-5-59>.
- [259] Sjöstrand M, Ambrosi A, Brauner S, Sullivan J, Malin S, Kuchroo VK, et al. Expression of the Immune Regulator Tripartite-Motif 21 Is Controlled by IFN Regulatory Factors. *The Journal of Immunology* 2013;191:3753–63. <https://doi.org/10.4049/jimmunol.1202341>.
- [260] Gao B, Xu W, Wang Y, Zhong L, Xiong S. Induction of TRIM22 by IFN- γ Involves JAK and PC-PLC/PKC, but Not MAPKs and pI3K/Akt/mTOR Pathways. *Journal of Interferon & Cytokine Research* 2013;33:578–87. <https://doi.org/10.1089/jir.2012.0170>.
- [261] Twentyman J, Khalifeh A, Felton AL, Emerman M, Ohainle M. Primate TRIM34 is a broadly-acting, TRIM5-dependent lentiviral restriction factor. *Retrovirology* 2023;20:1–14. <https://doi.org/10.1186/S12977-023-00629-4/FIGURES/4>.
- [262] Song M, Ping Y, Zhang K, Yang L, Li F, Zhang C, et al. Low-Dose IFN γ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer. *Cancer Res* 2019;79:3737–48. <https://doi.org/10.1158/0008-5472.CAN-19-0596>.
- [263] Imai Y, Chiba T, Kondo T, Kanzaki H, Kanayama K, Ao J, et al. Interferon- γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer. *Oncol Lett* 2020;20:2161. <https://doi.org/10.3892/OL.2020.11757>.
- [264] Yin H, Jiang Z, Wang S, Zhang P. IFN- γ restores the impaired function of RNase L and induces mitochondria-mediated apoptosis in lung cancer. *Cell Death Dis* 2019;10:642. <https://doi.org/10.1038/s41419-019-1902-9>.
- [265] Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. *Cell Death Differ* 1998;5:551–62. <https://doi.org/10.1038/sj.cdd.4400404>.

- [266] Vila-del Sol V, Punzón C, Fresno M. IFN- γ -Induced TNF- α Expression Is Regulated by Interferon Regulatory Factors 1 and 8 in Mouse Macrophages. *The Journal of Immunology* 2008;181:4461–70. <https://doi.org/10.4049/jimmunol.181.7.4461>.
- [267] Boutsikou E, Domvri K, Hardavella G, Tsiouda D, Zarogoulidis K, Kontakiotis T. Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. *Ther Adv Med Oncol* 2018;10:175883591876823. <https://doi.org/10.1177/1758835918768238>.
- [268] Fang C, Weng T, Hu S, Yuan Z, Xiong H, Huang B, et al. IFN- γ -induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells. *Oncoimmunology* 2021;10. <https://doi.org/10.1080/2162402X.2021.1962591>.
- [269] Tomar D, Singh R, Singh AK, Pandya CD, Singh R. TRIM13 regulates ER stress induced autophagy and clonogenic ability of the cells. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* 2012;1823:316–26. <https://doi.org/10.1016/j.bbamcr.2011.11.015>.
- [270] An X, Ji B, Sun D. TRIM34 localizes to the mitochondria and mediates apoptosis through the mitochondrial pathway in HEK293T cells. *Heliyon* 2020;6:e03115. <https://doi.org/10.1016/j.heliyon.2019.e03115>.
- [271] Wartha F, Henriques-Normark B. ETosis: A Novel Cell Death Pathway. *Sci Signal* 2008;1. <https://doi.org/10.1126/stke.121pe25>.
- [272] Lin C-F, Chien S-Y, Chen C-L, Hsieh C-Y, Tseng P-C, Wang Y-C. IFN- γ Induces Mimic Extracellular Trap Cell Death in Lung Epithelial Cells Through Autophagy-Regulated DNA Damage. *Journal of Interferon & Cytokine Research* 2016;36:100–12. <https://doi.org/10.1089/jir.2015.0011>.
- [273] Popper HH. Progression and metastasis of lung cancer. *Cancer and Metastasis Reviews* 2016;35:75–91. <https://doi.org/10.1007/s10555-016-9618-0>.
- [274] Yang J, Wang X, Huang B, Liu R, Xiong H, Ye F, et al. An IFN γ /STAT1/JMJD3 Axis Induces ZEB1 Expression and Promotes Aggressiveness in Lung Adenocarcinoma. *Molecular Cancer Research* 2021;19:1234–46. <https://doi.org/10.1158/1541-7786.MCR-20-0948>.
- [275] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–424. <https://doi.org/10.3322/caac.21492>.

- [276] Savić N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. *Translational Research* 2016;168:15–21. <https://doi.org/10.1016/j.trsl.2015.09.008>.
- [277] Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9. *FEBS Journal* 2014;281:5186–93. <https://doi.org/10.1111/febs.13110>.
- [278] Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, et al. CRISPR-Cas9 system: A new-fangled dawn in gene editing. *Life Sci* 2019;232:116636. <https://doi.org/10.1016/j.lfs.2019.116636>.
- [279] Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. *Drug Deliv* 2018;25:1234–57. <https://doi.org/10.1080/10717544.2018.1474964>.
- [280] Liu W, Yang C, Liu Y, Jiang G. CRISPR/Cas9 System and its Research Progress in Gene Therapy. *Anticancer Agents Med Chem* 2020;19:1912–9. <https://doi.org/10.2174/1871520619666191014103711>.
- [281] Karimian A, Azizian K, Parsian H, Rafieian S, Shafiei-Irannejad V, Kheyrollah M, et al. CRISPR/Cas9 technology as a potent molecular tool for gene therapy. *J Cell Physiol* 2019;234:12267–77. <https://doi.org/10.1002/jcp.27972>.
- [282] Cho S, Shin J, Cho B-K. Applications of CRISPR/Cas System to Bacterial Metabolic Engineering. *Int J Mol Sci* 2018;19:1089. <https://doi.org/10.3390/ijms19041089>.
- [283] Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science* (1979) 2014;346. <https://doi.org/10.1126/science.1258096>.
- [284] Mengstie MA, Wondimu BZ. Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. *Biologics* 2021;Volume 15:353–61. <https://doi.org/10.2147/BTT.S326422>.
- [285] Hossain MA. CRISPR-Cas9: A fascinating journey from bacterial immune system to human gene editing, 2021, p. 63–83. <https://doi.org/10.1016/bs.pmbts.2021.01.001>.
- [286] Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. *Mol Cancer* 2021;20:126. <https://doi.org/10.1186/s12943-021-01431-6>.
- [287] Tavakoli K, Pour-Aboughadareh A, Kianersi F, Poczaï P, Etminan A, Shooshtari L. Applications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences. *BioTech* 2021;10:14. <https://doi.org/10.3390/biotech10030014>.
- [288] Cong L, Zhang F. *Genome Engineering Using CRISPR-Cas9 System*, 2015, p. 197–217. https://doi.org/10.1007/978-1-4939-1862-1_10.

- [289] Zhu H, Li C, Gao C. Applications of CRISPR–Cas in agriculture and plant biotechnology. *Nat Rev Mol Cell Biol* 2020;21:661–77. <https://doi.org/10.1038/s41580-020-00288-9>.
- [290] Hryhorowicz M, Lipiński D, Zeyland J, Słomski R. CRISPR/Cas9 Immune System as a Tool for Genome Engineering. *Arch Immunol Ther Exp (Warsz)* 2017;65:233–40. <https://doi.org/10.1007/s00005-016-0427-5>.
- [291] Zhang C, Quan R, Wang J. Development and application of CRISPR/Cas9 technologies in genomic editing. *Hum Mol Genet* 2018;27:R79–88. <https://doi.org/10.1093/hmg/ddy120>.
- [292] Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* 2004;1695:55–72. <https://doi.org/10.1016/j.bbamcr.2004.09.019>.
- [293] Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. *Mol Cancer* 2020;19:146. <https://doi.org/10.1186/s12943-020-01262-x>.
- [294] Zou T, Lin Z. The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression. *Int J Mol Sci* 2021;22:5754. <https://doi.org/10.3390/ijms22115754>.
- [295] Ye Z, Yang J, Jiang H, Zhan X. The roles of protein ubiquitination in tumorigenesis and targeted drug discovery in lung cancer. *Front Endocrinol (Lausanne)* 2023;14. <https://doi.org/10.3389/fendo.2023.1220108>.
- [296] Tao J, Luo M, Sun H, Zhao H, Sun Q, Huang Z. Overexpression of tripartite motif containing 26 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling. *Kaohsiung J Med Sci* 2020;36:417–22. <https://doi.org/10.1002/kjm2.12194>.
- [297] Xu L, Wu Q, Zhou X, Wu Q, Fang M. TRIM13 inhibited cell proliferation and induced cell apoptosis by regulating NF-κB pathway in non-small-cell lung carcinoma cells. *Gene* 2019;715:144015. <https://doi.org/10.1016/j.gene.2019.144015>.
- [298] Rajsbaum R, García-Sastre A, Versteeg GA. TRIMmunity: The Roles of the TRIM E3-Ubiquitin Ligase Family in Innate Antiviral Immunity. *J Mol Biol* 2014;426:1265–84. <https://doi.org/10.1016/j.jmb.2013.12.005>.
- [299] Ohainle M, Kim K, Keceli SK, Felton A, Campbell E, Luban J, et al. TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner. *PLoS Pathog* 2020;16:1–22. <https://doi.org/10.1371/journal.ppat.1008507>.
- [300] Wang X, Xiong J, Zhou D, Zhang S, Wang L, Tian Q, et al. TRIM34 modulates influenza virus-activated programmed cell death by targeting Z-DNA-binding protein 1 for K63-linked

- polyubiquitination. *Journal of Biological Chemistry* 2022;298:101611. <https://doi.org/10.1016/j.jbc.2022.101611>.
- [301] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. *Genome Res* 2003;13:2498–504. <https://doi.org/10.1101/gr.1239303>.
- [302] Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 2014;8:S11. <https://doi.org/10.1186/1752-0509-8-S4-S11>.
- [303] Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: A free online platform for data visualization and graphing. *PLoS One* 2023;18:e0294236. <https://doi.org/10.1371/journal.pone.0294236>.
- [304] Okamoto M, Kouwaki T, Fukushima Y, Oshiumi H. Regulation of RIG-I Activation by K63-Linked Polyubiquitination. *Front Immunol* 2018;8. <https://doi.org/10.3389/fimmu.2017.01942>.
- [305] Maelfait J, Beyaert R. Emerging Role of Ubiquitination in Antiviral RIG-I Signaling. *Microbiology and Molecular Biology Reviews* 2012;76:33–45. <https://doi.org/10.1128/MMBR.05012-11>.
- [306] Kuser-Abali G, Zhang Y, Szeto P, Zhao P, Masoumi-Moghaddam S, Fedele CG, et al. UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. *Oncogene* 2023;42:1360–73. <https://doi.org/10.1038/s41388-023-02631-8>.
- [307] Li L, Bai J, Fan H, Yan J, Li S, Jiang P. E2 ubiquitin-conjugating enzyme UBE2L6 promotes Senecavirus A proliferation by stabilizing the viral RNA polymerase. *PLoS Pathog* 2020;16:e1008970. <https://doi.org/10.1371/journal.ppat.1008970>.
- [308] Beck DB, Werner A, Kastner DL, Aksentijevich I. Disorders of ubiquitylation: unchained inflammation. *Nat Rev Rheumatol* 2022;18:435–47. <https://doi.org/10.1038/s41584-022-00778-4>.
- [309] Liao Y, Sumara I, Pangou E. Non-proteolytic ubiquitylation in cellular signaling and human disease. *Commun Biol* 2022;5:114. <https://doi.org/10.1038/s42003-022-03060-1>.
- [310] Ma P, Mao B. The many faces of the E3 ubiquitin ligase, RNF220, in neural development and beyond. *Dev Growth Differ* 2022;64:98–105. <https://doi.org/10.1111/dgd.12756>.

- [311] Cruz Walma DA, Chen Z, Bullock AN, Yamada KM. Ubiquitin ligases: guardians of mammalian development. *Nat Rev Mol Cell Biol* 2022;23:350–67. <https://doi.org/10.1038/s41580-021-00448-5>.
- [312] Diehl WE, Johnson WE, Hunter E. Elevated Rate of Fixation of Endogenous Retroviral Elements in Haplorhini TRIM5 and TRIM22 Genomic Sequences: Impact on Transcriptional Regulation. *PLoS One* 2013;8:e58532. <https://doi.org/10.1371/journal.pone.0058532>.
- [313] Liang Y, Wang H, Chen B, Mao Q, Xia W, Zhang T, et al. circDCUN1D4 suppresses tumor metastasis and glycolysis in lung adenocarcinoma by stabilizing TXNIP expression. *Mol Ther Nucleic Acids* 2021;23:355–68. <https://doi.org/10.1016/j.omtn.2020.11.012>.
- [314] Li Y, Miao L-Y, Xiao Y-L, Huang M, Yu M, Meng K, et al. Hypoxia Induced High Expression of Thioredoxin Interacting Protein (TXNIP) in Non-small Cell Lung Cancer and its Prognostic Effect. *Asian Pacific Journal of Cancer Prevention* 2015;16:2953–8. <https://doi.org/10.7314/APJCP.2015.16.7.2953>.
- [315] Kim GT, Kim EY, Shin S-H, Lee H, Lee SH, Sohn K-Y, et al. Suppression of tumor progression by thioredoxin-interacting protein-dependent adenosine 2B receptor degradation in a PLAG-treated Lewis lung carcinoma-1 model of non-small cell lung cancer. *Neoplasia* 2022;31:100815. <https://doi.org/10.1016/j.neo.2022.100815>.
- [316] Tang J-Y, Li D-Y, He L, Qiu X-S, Wang E-H, Wu G-P. HPV 16 E6/E7 Promote the Glucose Uptake of GLUT1 in Lung Cancer Through Downregulation of TXNIP Due to Inhibition of PTEN Phosphorylation. *Front Oncol* 2020;10. <https://doi.org/10.3389/fonc.2020.559543>.
- [317] Sun Q, Wang B, Wei W, Huang G, Liu L, Chen W, et al. *ITCH* facilitates proteasomal degradation of *TXNIP* in hypoxia-induced lung cancer cells. *Thoracic Cancer* 2022;13:2235–47. <https://doi.org/10.1111/1759-7714.14552>.
- [318] Li Y, Yang L. Cyclophilin a represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein. *Cell Cycle* 2022;21:1996–2007. <https://doi.org/10.1080/15384101.2022.2078615>.
- [319] Cheng Z, Lu C, Wang H, Wang N, Cui S, Yu C, et al. Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression. *Cancer Lett* 2022;531:1–13. <https://doi.org/10.1016/j.canlet.2022.01.031>.
- [320] Shi Y, Jin Y, Liu F, Jiang J, Cao J, Lu Y, et al. Ceramide induces the apoptosis of non-small cell lung cancer cells through the Txnip/Trx1 complex. *Int J Mol Med* 2021;47:85. <https://doi.org/10.3892/ijmm.2021.4918>.

- [321] Xiao X, Xu Y, Chen H. Sodium butyrate-activated TRAF6-TXNIP pathway affects A549 cells proliferation and migration. *Cancer Med* 2020;9:3477–88. <https://doi.org/10.1002/cam4.2564>.
- [322] Gong J, Ma L, Peng C, Liu J. LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis. *Ann Transl Med* 2021;9:1793–1793. <https://doi.org/10.21037/atm-21-6466>.
- [323] Becker AC, Gannagé M, Giese S, Hu Z, Abou-Eid S, Roubaty C, et al. Influenza A Virus Induces Autophagosomal Targeting of Ribosomal Proteins. *Molecular & Cellular Proteomics* 2018;17:1909–21. <https://doi.org/10.1074/mcp.RA117.000364>.
- [324] Liao X-H, Wang Y, Zhong B, Zhu S-Y. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4. *Eur Rev Med Pharmacol Sci* 2020;24:3143–51. https://doi.org/10.26355/eurev_202003_20681.
- [325] Liu X, Lu Y, Chen Z, Liu X, Hu W, Zheng L, et al. The Ubiquitin-Specific Peptidase USP18 Promotes Lipolysis, Fatty Acid Oxidation, and Lung Cancer Growth. *Molecular Cancer Research* 2021;19:667–77. <https://doi.org/10.1158/1541-7786.MCR-20-0579>.
- [326] Chen Z, Zheng L, Chen Y, Liu X, Kawakami M, Mustachio LM, et al. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3 ζ protein and represses lung cancer metastasis. *Cancer Biol Ther* 2022;23:265–80. <https://doi.org/10.1080/15384047.2022.2054242>.
- [327] Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F, et al. miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. *Mol Cancer* 2014;13:166. <https://doi.org/10.1186/1476-4598-13-166>.
- [328] Yan Q, Ding J, Khan SJ, Lawton LN, Shipp MA. DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites. *IScience* 2023;26:106444. <https://doi.org/10.1016/j.isci.2023.106444>.
- [329] Li Y, Liu H, Wang J, Li Y, Wu H, Du X, et al. [BAG family gene and its relationship with lung adenocarcinoma susceptibility]. *Zhongguo Fei Ai Za Zhi* 2010;13:942–6. <https://doi.org/10.3779/j.issn.1009-3419.2010.10.03>.
- [330] Yu P, Liang P, Pang S, Yuan W, Zhao Y, Huang Q. The Function, Role and Process of DDX58 in Heart Failure and Human Cancers. *Front Oncol* 2022;12:911309. <https://doi.org/10.3389/FONC.2022.911309/BIBTEX>.
- [331] Hung M-S, Chen Y-C, Lin P-Y, Li Y-C, Hsu C-C, Lung J-H, et al. Cul4A Modulates Invasion and Metastasis of Lung Cancer through Regulation of ANXA10. *Cancers (Basel)* 2019;11:618. <https://doi.org/10.3390/cancers11050618>.

- [332] Wang Y, Zhang P, Liu Z, Wang Q, Wen M, Wang Y, et al. CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to Erlotinib via transcriptional regulation of EGFR. *Mol Cancer* 2014;13:252. <https://doi.org/10.1186/1476-4598-13-252>.
- [333] Hung M, Chen I, You L, Jablons DM, Li Y, Mao J, et al. Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells. *J Cell Mol Med* 2016;20:1295–306. <https://doi.org/10.1111/jcmm.12811>.
- [334] Cao P, Chen W, Pang H, Shen W, Xue P, Duan L, et al. Effect of CUL4A on the metastatic potential of lung adenocarcinoma to the bone. *Oncol Rep* 2019. <https://doi.org/10.3892/or.2019.7448>.
- [335] Mao C, Jiang S, Shen C, Long T, Jin H, Tan Q, et al. <scp>BCAR1</scp> promotes proliferation and cell growth in lung adenocarcinoma via upregulation of <scp>POLR2A</scp>. *Thorac Cancer* 2020;11:3326–36. <https://doi.org/10.1111/1759-7714.13676>.
- [336] Watanabe K, Yokoyama S, Kaneto N, Hori T, Iwakami Y, Kato S, et al. COP9 signalosome subunit 5 regulates cancer metastasis by deubiquitinating SNAIL. *Oncotarget* 2018;9:20670–80. <https://doi.org/10.18632/oncotarget.25060>.
- [337] Hou J, Liu G, Yuan Y, Wang D, Jiao P, Xing L, et al. Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients. *Oncotarget* 2017;8:97504–15. <https://doi.org/10.18632/oncotarget.22146>.
- [338] Chang H, Liu Y-H, Wang L-L, Wang J, Zhao Z-H, Qu J-F, et al. MiR-182 promotes cell proliferation by suppressing FBXW7 and FBXW11 in non-small cell lung cancer. *Am J Transl Res* 2018;10:1131–42.
- [339] Wraage M, Hagmann W, Kemming D, Uzunoglu FG, Riethdorf S, Effenberger K, et al. Identification of <scp>HERC</scp> 5 and its potential role in <scp>NSCLC</scp> progression. *Int J Cancer* 2015;136:2264–72. <https://doi.org/10.1002/ijc.29298>.
- [340] Zhang K, Lin G, Nie Z, Jin S, Bing X, Li Z, et al. TRIM38 suppresses migration, invasion, metastasis, and proliferation in non-small cell lung cancer (NSCLC) via regulating the AMPK/NF-κB/NLRP3 pathway. *Mol Cell Biochem* 2023. <https://doi.org/10.1007/s11010-023-04823-y>.
- [341] CHEN Y, GAO Y, TIAN Y, TIAN D-L. PRKACB is downregulated in non-small cell lung cancer and exogenous PRKACB inhibits proliferation and invasion of LTEP-A2 cells. *Oncol Lett* 2013;5:1803–8. <https://doi.org/10.3892/ol.2013.1294>.

- [342] KIM B, SOHN EJ, JUNG JH, SHIN EA, YOU OH, IM J, et al. Inhibition of ZNF746 suppresses invasion and epithelial to mesenchymal transition in H460 non-small cell lung cancer cells. *Oncol Rep* 2014;31:73–8. <https://doi.org/10.3892/or.2013.2801>.
- [343] Zhang P, Li L, Wang B, Ran X, Yang S, Luo Y, et al. miR-489-3p promotes malignant progression of non-small cell lung cancer through the inactivation of Wnt/ β -catenin signaling pathway via regulating USP48. *Respir Res* 2022;23:93. <https://doi.org/10.1186/s12931-022-01988-w>.
- [344] Zhou Y, Wan C, Liu Y, Lv L, Chen B, Ni R, et al. Polycomb Group Oncogene RING1 is Over-expressed in Non-Small Cell Lung Cancer. *Pathology & Oncology Research* 2014;20:549–56. <https://doi.org/10.1007/s12253-013-9727-9>.
- [345] Langevin SM, Kratzke RA, Kelsey KT. Epigenetics of lung cancer. *Translational Research* 2015;165:74–90. <https://doi.org/10.1016/j.trsl.2014.03.001>.
- [346] Kanwal R, Gupta S. Epigenetic modifications in cancer. *Clin Genet* 2012;81:303–11. <https://doi.org/10.1111/j.1399-0004.2011.01809.x>.
- [347] Triantaphyllopoulos KA, Ikonomopoulos I, Bannister AJ. Epigenetics and inheritance of phenotype variation in livestock. *Epigenetics Chromatin* 2016;9:31. <https://doi.org/10.1186/s13072-016-0081-5>.
- [348] Marczylo EL, Jacobs MN, Gant TW. Environmentally induced epigenetic toxicity: potential public health concerns. *Crit Rev Toxicol* 2016;46:676–700. <https://doi.org/10.1080/10408444.2016.1175417>.
- [349] Dan H, Zhang S, Zhou Y, Guan Q. <p>DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses</p>. *Onco Targets Ther* 2019;Volume 12:10903–16. <https://doi.org/10.2147/OTT.S217767>.
- [350] Waterland RA. Epigenetic mechanisms and gastrointestinal development. *J Pediatr* 2006;149:S137–42. <https://doi.org/10.1016/j.jpeds.2006.06.064>.
- [351] Li Y. Modern epigenetics methods in biological research. *Methods* 2021;187:104–13. <https://doi.org/10.1016/j.ymeth.2020.06.022>.
- [352] Dumitrescu RG. Epigenetic Markers of Early Tumor Development, 2012, p. 3–14. https://doi.org/10.1007/978-1-61779-612-8_1.

- [353] Kozomara Z, Supic G, Krivokuca A, Magic Z, Dzodic R, Milovanovic Z, et al. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia. *J BUON* 2018;23:684–91.
- [354] Lo P-K, Sukumar S. Epigenomics and breast cancer. *Pharmacogenomics* 2008;9:1879–902. <https://doi.org/10.2217/14622416.9.12.1879>.
- [355] Brzeziańska E, Dutkowska A, Antczak A. The significance of epigenetic alterations in lung carcinogenesis. *Mol Biol Rep* 2013;40:309–25. <https://doi.org/10.1007/s11033-012-2063-4>.
- [356] Hong Y, Kim WJ. DNA Methylation Markers in Lung Cancer. *Curr Genomics* 2021;22:79–87. <https://doi.org/10.2174/1389202921999201013164110>.
- [357] Hoang PH, Landi MT. DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors. *Cancers (Basel)* 2022;14:961. <https://doi.org/10.3390/cancers14040961>.
- [358] Zöchbauer-Müller S, Minna JD, Gazdar AF. Aberrant DNA Methylation in Lung Cancer: Biological and Clinical Implications. *Oncologist* 2002;7:451–7. <https://doi.org/10.1634/theoncologist.7-5-451>.
- [359] Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, et al. Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk. *Clinical Cancer Research* 2005;11:6505–11. <https://doi.org/10.1158/1078-0432.CCR-05-0625>.
- [360] Chung J-H, Lee HJ, Kim B, Cho N-Y, Kang GH. DNA methylation profile during multistage progression of pulmonary adenocarcinomas. *Virchows Archiv* 2011;459:201–11. <https://doi.org/10.1007/s00428-011-1079-9>.
- [361] Licchesi JDF, Westra WH, Hooker CM, Herman JG. Promoter Hypermethylation of Hallmark Cancer Genes in Atypical Adenomatous Hyperplasia of the Lung. *Clinical Cancer Research* 2008;14:2570–8. <https://doi.org/10.1158/1078-0432.CCR-07-2033>.
- [362] Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ, et al. Examination of a CpG Island Methylator Phenotype and Implications of Methylation Profiles in Solid Tumors. *Cancer Res* 2006;66:10621–9. <https://doi.org/10.1158/0008-5472.CAN-06-1687>.
- [363] Liu Z, Zhao J, Chen X-F, Li W, Liu R, Lei Z, et al. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. *Lung Cancer* 2008;62:15–22. <https://doi.org/10.1016/j.lungcan.2008.02.005>.

- [364] Shinjo K, Okamoto Y, An B, Yokoyama T, Takeuchi I, Fujii M, et al. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. *Carcinogenesis* 2012;33:1277–85. <https://doi.org/10.1093/carcin/bgs154>.
- [365] Lin R-K, Hsu H-S, Chang J-W, Chen C-Y, Chen J-T, Wang Y-C. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. *Lung Cancer* 2007;55:205–13. <https://doi.org/10.1016/j.lungcan.2006.10.022>.
- [366] Miller JL, Grant PA. The Role of DNA Methylation and Histone Modifications in Transcriptional Regulation in Humans, 2013, p. 289–317. https://doi.org/10.1007/978-94-007-4525-4_13.
- [367] Moore LD, Le T, Fan G. DNA Methylation and Its Basic Function. *Neuropsychopharmacology* 2013;38:23–38. <https://doi.org/10.1038/npp.2012.112>.
- [368] GRØNBAEK K, HOTHER C, JONES PA. Epigenetic changes in cancer. *APMIS* 2007;115:1039–59. https://doi.org/10.1111/j.1600-0463.2007.apm_636.xml.x.
- [369] Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 2002;3:415–28. <https://doi.org/10.1038/nrg816>.
- [370] Momparler RL. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). *Semin Hematol* 2005;42:S9–16. <https://doi.org/10.1053/j.seminhematol.2005.05.002>.
- [371] Issa J-P, Kantarjian H, Kirkpatrick P. Azacitidine. *Nat Rev Drug Discov* 2005;4:S6–7. <https://doi.org/10.1038/nrd1726>.
- [372] Issa J-P. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. *Nat Clin Pract Oncol* 2005;2:S24–9. <https://doi.org/10.1038/ncponc0355>.
- [373] Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional Diversity of DNA Methyltransferase Inhibitors in Human Cancer Cell Lines. *Cancer Res* 2006;66:2794–800. <https://doi.org/10.1158/0008-5472.CAN-05-2821>.
- [374] Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. *Oncogene* 2002;21:5483–95. <https://doi.org/10.1038/sj.onc.1205699>.
- [375] Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, et al. Phase I Trial of Sequential Low-Dose 5-Aza-2'-Deoxycytidine Plus High-Dose Intravenous Bolus

- Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma. *Clinical Cancer Research* 2006;12:4619–27. <https://doi.org/10.1158/1078-0432.CCR-06-0883>.
- [376] Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms. *Cancer Res* 2006;66:6361–9. <https://doi.org/10.1158/0008-5472.CAN-06-0080>.
- [377] Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Pan X, et al. Alterations of immune response of non-small cell lung cancer with Azacytidine. *Oncotarget* 2013;4:2067–79. <https://doi.org/10.18632/oncotarget.1542>.
- [378] Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, et al. TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. *Oncotarget* 2014;5:10127–39. <https://doi.org/10.18632/oncotarget.2466>.
- [379] Wang S, Zhang Y, Huang J, Wong CC, Zhai J, Li C, et al. TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression. *Cancer Res* 2019;79:4086–98. <https://doi.org/10.1158/0008-5472.CAN-18-3614>.
- [380] Shi Y-X. Identification of the molecular function of tripartite motif containing 58 in human lung cancer. *Oncol Lett* 2021;22:685. <https://doi.org/10.3892/ol.2021.12946>.
- [381] Li L-C, Dahiya R. MethPrimer: designing primers for methylation PCRs. *Bioinformatics* 2002;18:1427–31. <https://doi.org/10.1093/bioinformatics/18.11.1427>.
- [382] Moore LD, Le T, Fan G. DNA Methylation and Its Basic Function. *Neuropsychopharmacology* 2013;38:23–38. <https://doi.org/10.1038/npp.2012.112>.
- [383] Pajares MJ, Palanca-Ballester C, Urtasun R, Alemany-Cosme E, Lahoz A, Sandoval J. Methods for analysis of specific DNA methylation status. *Methods* 2021;187:3–12. <https://doi.org/10.1016/j.ymeth.2020.06.021>.
- [384] Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J, et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. *Cancer* 2006;107:1042–9. <https://doi.org/10.1002/cncr.22087>.
- [385] Lin R-K, Wu C-Y, Chang J-W, Juan L-J, Hsu H-S, Chen C-Y, et al. Dysregulation of p53/Sp1 Control Leads to DNA Methyltransferase-1 Overexpression in Lung Cancer. *Cancer Res* 2010;70:5807–17. <https://doi.org/10.1158/0008-5472.CAN-09-4161>.
- [386] Yang Y-C, Tang Y-A, Shieh J-M, Lin R-K, Hsu H-S, Wang Y-C. DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression

- in Lung Cancer. *Journal of Thoracic Oncology* 2014;9:1305–15. <https://doi.org/10.1097/JTO.0000000000000240>.
- [387] Tang Y-A, Lin R-K, Tsai Y-T, Hsu H-S, Yang Y-C, Chen C-Y, et al. MDM2 Overexpression Deregulates the Transcriptional Control of RB/E2F Leading to DNA Methyltransferase 3A Overexpression in Lung Cancer. *Clinical Cancer Research* 2012;18:4325–33. <https://doi.org/10.1158/1078-0432.CCR-11-2617>.
- [388] Herman JG. Hypermethylation of tumor suppressor genes in cancer. *Semin Cancer Biol* 1999;9:359–67. <https://doi.org/10.1006/SCBI.1999.0138>.
- [389] Huang T, Chen X, Hong Q, Deng Z, Ma H, Xin Y, et al. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. *Sci Rep* 2015;5:8897. <https://doi.org/10.1038/srep08897>.
- [390] Al-Yozbaki M, Jabre I, Syed NH, Wilson CM. Targeting DNA methyltransferases in non-small-cell lung cancer. *Semin Cancer Biol* 2022;33:77–87. <https://doi.org/10.1016/J.SEMCANCER.2021.01.005>.
- [391] Scopus preview - Scopus - Document details - DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells n.d. <https://www.scopus.com/record/display.uri?eid=2-s2.0-0037224722&origin=inward&txGid=683a49e4bcf151d6cac8939a9e376094> (accessed April 27, 2023).
- [392] Li C, Ebert PJR, Li Q-J. T Cell Receptor (TCR) and Transforming Growth Factor β (TGF- β) Signaling Converge on DNA (Cytosine-5)-methyltransferase to Control forkhead box protein 3 (foxp3) Locus Methylation and Inducible Regulatory T Cell Differentiation. *Journal of Biological Chemistry* 2013;288:19127–39. <https://doi.org/10.1074/jbc.M113.453357>.
- [393] Chiappinelli KB, Zahnow CA, Ahuja N, Bylin SB. Combining Epigenetic and Immunotherapy to Combat Cancer. *Cancer Res* 2016;76:1683–9. <https://doi.org/10.1158/0008-5472.CAN-15-2125>.
- [394] Karpf AR, Peterson PW, Rawlins JT, Dalley BK, Yang Q, Albertsen H, et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. *Proc Natl Acad Sci U S A* 1999;96:14007–12. <https://doi.org/10.1073/PNAS.96.24.14007/ASSET/1B516BCB-1C34-4FF2-AF68-D8F7496D733B/ASSETS/GRAPHIC/PQ2494087005.JPEG>.

- [395] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin* 2022;72:7–33. <https://doi.org/10.3322/caac.21708>.
- [396] Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. *SAGE Open Med* 2021;9:205031212110343. <https://doi.org/10.1177/20503121211034366>.
- [397] Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a Preventable Disease that Requires Major Lifestyle Changes. *Pharm Res* 2008;25:2097–116. <https://doi.org/10.1007/s11095-008-9661-9>.
- [398] Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. *Mol Oncol* 2021;15:790–800. <https://doi.org/10.1002/1878-0261.12772>.
- [399] Huang T, Chen X, Hong Q, Deng Z, Ma H, Xin Y, et al. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. *Sci Rep* 2015;5:8897. <https://doi.org/10.1038/srep08897>.
- [400] Hu X, Wang J, Chu M, Liu Y, Wang Z, Zhu X. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy. *Molecular Therapy* 2021;29:908–19. <https://doi.org/10.1016/j.ymthe.2020.12.032>.
- [401] Pan M, Blattner C. Regulation of p53 by E3s. *Cancers (Basel)* 2021;13:745. <https://doi.org/10.3390/cancers13040745>.
- [402] Deshmukh D, Xu J, Yang X, Shimelis H, Fang S, Qiu Y. Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6. *Pharmaceutics* 2022;14:802. <https://doi.org/10.3390/pharmaceutics14040802>.
- [403] Mattern MR, Wu J, Nicholson B. Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* 2012;1823:2014–21. <https://doi.org/10.1016/j.bbamcr.2012.05.005>.
- [404] Koliopoulos MG, Esposito D, Christodoulou E, Taylor IA, Rittinger K. Functional role of TRIM E3 ligase oligomerization and regulation of catalytic activity . *EMBO J* 2016;35:1204–18. <https://doi.org/10.15252/EMBJ.201593741>.
- [405] Zhan W, Zhang S. TRIM proteins in lung cancer: Mechanisms, biomarkers and therapeutic targets. *Life Sci* 2021;268:118985. <https://doi.org/10.1016/j.lfs.2020.118985>.

- [406] Rajsbaum R, Stoye JP, O'Garra A. Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells. *Eur J Immunol* 2008;38:619–30. <https://doi.org/10.1002/eji.200737916>.
- [407] Wu W, Yang B, Qiao Y, Zhou Q, He H, He M. Kaempferol protects mitochondria and alleviates damages against endotheliotoxicity induced by doxorubicin. *Biomedicine & Pharmacotherapy* 2020;126:110040. <https://doi.org/10.1016/j.biopha.2020.110040>.
- [408] Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, et al. BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly. *Mol Cell* 2005;17:525–35. <https://doi.org/10.1016/j.molcel.2005.02.003>.
- [409] Madan S, Uttekar B, Chowdhary S, Rikhy R. Mitochondria Lead the Way: Mitochondrial Dynamics and Function in Cellular Movements in Development and Disease. *Front Cell Dev Biol* 2022;9. <https://doi.org/10.3389/fcell.2021.781933>.
- [410] Vasan K, Clutter M, Fernandez Dunne S, George MD, Luan C-H, Chandel NS, et al. Genes Involved in Maintaining Mitochondrial Membrane Potential Upon Electron Transport Chain Disruption. *Front Cell Dev Biol* 2022;10. <https://doi.org/10.3389/fcell.2022.781558>.
- [411] Deng Y, Fu H, Han X, Li Y, Zhao W, Zhao X, et al. Activation of DDX58/RIG-I suppresses the growth of tumor cells by inhibiting STAT3/CSE signaling in colon cancer. *Int J Oncol* 2022;61:120. <https://doi.org/10.3892/ijo.2022.5410>.
- [412] Song L-B, Zhang Q-J, Hou X-Y, Xiu Y-Y, Chen L, Song N-H, et al. A twelve-gene signature for survival prediction in malignant melanoma patients. *Ann Transl Med* 2020;8:312–312. <https://doi.org/10.21037/atm.2020.02.132>.
- [413] Kuser-Abali G, Zhang Y, Szeto P, Zhao P, Masoumi-Moghaddam S, Fedele CG, et al. UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. *Oncogene* 2023;42:1360–73. <https://doi.org/10.1038/s41388-023-02631-8>.